Terns Pharmaceuticals, Inc. Ending Cash

Ending Cash of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Ending Cash growth rates and interactive chart.


Highlights and Quick Summary

  • Ending Cash for the quarter ending March 31, 2022 was $43.9 Million (a -357.32% decrease compared to previous quarter)
  • Year-over-year quarterly Ending Cash decreased by -240.46%
  • Annual Ending Cash for 2021 was $47.7 Million (a -36.28% decrease from previous year)
  • Annual Ending Cash for 2020 was $74.9 Million (a 504.88% increase from previous year)
  • Twelve month Ending Cash ending March 31, 2022 was $-7.25 Million (a -115.2% decrease compared to previous quarter)
  • Twelve month trailing Ending Cash decreased by -105.9% year-over-year
Trailing Ending Cash for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$-7.25 Million $47.7 Million $126 Million $123 Million
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Ending Cash of Terns Pharmaceuticals, Inc.

Most recent Ending Cashof TERN including historical data for past 10 years.

Interactive Chart of Ending Cash of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Ending Cash for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $43.88
2021 $-17.05 $-2.84 $-31.24 $98.83 $47.7
2020 $61.05 $-5.83 $7.89 $11.74 $74.85
2019 $12.38 $12.38

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.